Wells Fargo analyst Stephen Baxter lowered the firm’s price target on CVS Health (CVS) to $102 from $103 and keeps an Overweight rating on the shares. Overall, results in Q3 were solid, but the bull case for HCB in 2025 moderates some on steeper Part D MLR, the firm says. Wells’ 2025 EPS estimate increases, with 2026 unchanged and modestly ahead of what CVS framed as a reasonable starting point for guidance.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS Health: Strategic Positioning and Growth Potential Justify Buy Rating Despite Challenges
- Trump Trade: Trump says ‘enrichment’ of health insurers ‘must stop’
- Video: Health insurers weighed on by shutdown news, Trump post
- Trump says ‘enrichment’ of health insurers ‘must stop’
- CVS Health price target raised to $100 from $99 at TD Cowen